These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 29875309)

  • 21. GBP1 promotes erlotinib resistance via PGK1‑activated EMT signaling in non‑small cell lung cancer.
    Cheng L; Gou L; Wei T; Zhang J
    Int J Oncol; 2020 Sep; 57(3):858-870. PubMed ID: 32582960
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The repression and reciprocal interaction of DNA methyltransferase 1 and specificity protein 1 contributes to the inhibition of MET expression by the combination of Chinese herbal medicine FZKA decoction and erlotinib.
    Zheng F; Zhao Y; Li X; Tang Q; Wu J; Wu W; Hann SS
    J Ethnopharmacol; 2019 Jul; 239():111928. PubMed ID: 31077779
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autophagy inhibition facilitates erlotinib cytotoxicity in lung cancer cells through modulation of endoplasmic reticulum stress.
    Wang Z; Du T; Dong X; Li Z; Wu G; Zhang R
    Int J Oncol; 2016 Jun; 48(6):2558-66. PubMed ID: 27035631
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines.
    Cavazzoni A; Alfieri RR; Cretella D; Saccani F; Ampollini L; Galetti M; Quaini F; Graiani G; Madeddu D; Mozzoni P; Galvani E; La Monica S; Bonelli M; Fumarola C; Mutti A; Carbognani P; Tiseo M; Barocelli E; Petronini PG; Ardizzoni A
    Mol Cancer; 2012 Dec; 11():91. PubMed ID: 23234355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The histone deacetylase SIRT6 promotes glycolysis through the HIF-1α/HK2 signaling axis and induces erlotinib resistance in non-small cell lung cancer.
    You Q; Wang J; Yu Y; Li F; Meng L; Chen M; Yang Q; Xu Z; Sun J; Zhuo W; Chen Z
    Apoptosis; 2022 Dec; 27(11-12):883-898. PubMed ID: 35915188
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death.
    Chen P; Huang HP; Wang Y; Jin J; Long WG; Chen K; Zhao XH; Chen CG; Li J
    J Exp Clin Cancer Res; 2019 Jun; 38(1):254. PubMed ID: 31196210
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fingolimod augments Pemetrexed killing of non-small cell lung cancer and overcomes resistance to ERBB inhibition.
    Booth L; Roberts JL; Spiegel S; Poklepovic A; Dent P
    Cancer Biol Ther; 2019; 20(5):597-607. PubMed ID: 30388910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
    Murphy M; Stordal B
    Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft model.
    Li H; Wang S; Takayama K; Harada T; Okamoto I; Iwama E; Fujii A; Ota K; Hidaka N; Kawano Y; Nakanishi Y
    Lung Cancer; 2015 Apr; 88(1):1-8. PubMed ID: 25670150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer.
    Bao R; Lai CJ; Wang DG; Qu H; Yin L; Zifcak B; Tao X; Wang J; Atoyan R; Samson M; Forrester J; Xu GX; DellaRocca S; Borek M; Zhai HX; Cai X; Qian C
    Mol Cancer Ther; 2009 Dec; 8(12):3296-306. PubMed ID: 19952121
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
    Naumov GN; Nilsson MB; Cascone T; Briggs A; Straume O; Akslen LA; Lifshits E; Byers LA; Xu L; Wu HK; Jänne P; Kobayashi S; Halmos B; Tenen D; Tang XM; Engelman J; Yeap B; Folkman J; Johnson BE; Heymach JV
    Clin Cancer Res; 2009 May; 15(10):3484-94. PubMed ID: 19447865
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.
    Sequist LV; Gray JE; Harb WA; Lopez-Chavez A; Doebele RC; Modiano MR; Jackman DM; Baggstrom MQ; Atmaca A; Felip E; Provencio M; Cobo M; Adiwijaya B; Kuesters G; Kamoun WS; Andreas K; Pipas JM; Santillana S; Cho BC; Park K; Shepherd FA
    Oncologist; 2019 Aug; 24(8):1095-1102. PubMed ID: 30975923
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells.
    Han W; Pan H; Chen Y; Sun J; Wang Y; Li J; Ge W; Feng L; Lin X; Wang X; Wang X; Jin H
    PLoS One; 2011; 6(6):e18691. PubMed ID: 21655094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs.
    Ahmad A; Maitah MY; Ginnebaugh KR; Li Y; Bao B; Gadgeel SM; Sarkar FH
    J Hematol Oncol; 2013 Oct; 6(1):77. PubMed ID: 24199791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer.
    Wang M; Zhao J; Zhang LM; Li H; Yu JP; Ren XB; Wang CL
    J Cancer Res Clin Oncol; 2012 Dec; 138(12):2069-77. PubMed ID: 22821179
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ACY-241, an HDAC6 inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by inducing autophagy.
    Park SJ; Joo SH; Lee N; Jang WJ; Seo JH; Jeong CH
    Arch Pharm Res; 2021 Dec; 44(12):1062-1075. PubMed ID: 34761352
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GATA6-upregulating autophagy promotes TKI resistance in nonsmall cell lung cancer.
    Ma R; Li X; Liu H; Jiang R; Yang M; Zhang M; Wang Y; Zhao Y; Li H
    Cancer Biol Ther; 2019; 20(9):1206-1212. PubMed ID: 31092103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression.
    Li H; Takayama K; Wang S; Shiraishi Y; Gotanda K; Harada T; Furuyama K; Iwama E; Ieiri I; Okamoto I; Nakanishi Y
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1297-305. PubMed ID: 25344762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
    Shi P; Oh YT; Zhang G; Yao W; Yue P; Li Y; Kanteti R; Riehm J; Salgia R; Owonikoko TK; Ramalingam SS; Chen M; Sun SY
    Cancer Lett; 2016 Oct; 380(2):494-504. PubMed ID: 27450722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.